Your Questions, Answered

We’ve assembled the most frequently asked questions about Eversense into one place. Got a question that you can’t find the answer to? Contact us.

Filter by topic:

The Eversense® 365 Sensor is implanted in the upper arm.

No. Re-linking does not impact the life of your sensor.

The Eversense® 365 Sensor does not contain any natural rubber latex.  It is considered latex free.

If you do not have access to a blood glucose meter when you receive a calibration prompt:

In the 1 Daily Calibration Phase:

If you do not calibrate within 48 hours, the system will display a Calibration Past Due Alert and no glucose values will be available until a calibration value is entered. After 72 hours without a calibration value entered, the system will display a Calibration Expired Alert and the system returns to Initialization Phase.

In the 1 Weekly Calibration Phase:

If you do not calibrate within 8 days from the time of your last successful calibration, the system will display a Calibration Past Due Alert and no glucose values will be available until a calibration value is entered. After 9 days without a calibration value entered, the system will display a Calibration Expired Alert and the system returns to Initialization Phase.

Calibration due.pngCalibration expired.png

Even with a non-adjunctive CGM system, you should always carry a blood glucose meter with you as you should always be prepared to take a blood glucose test when prompted for a calibration or when any of the following situations occur:

  • Your symptoms do not match the glucose value displayed on your app
  • No glucose value is displayed (during system initialization, for example)
  • No trend arrow is displayed
  • The current sensor glucose value is displayed in grey.
  • Your system prompts you to use your BG meter for making a treatment decision in the app status bar
  • You are taking medications of the tetracycline class

Once a new sensor is inserted by your health care professional and paired with the transmitter using the Eversense® App, it will start the 24-hour warm-up phase. Once the 24-hour warm-up phase is completed, you will begin the Initialization Phase.

Initialization Phase (after 24-hour Warm-Up Phase)

During this phase, 4 finger stick blood glucose meter tests are required.

  • The 4 calibration tests must be spaced 2 to 12 hours apart, and all 4 tests must be completed within a 36 hour period.
    • 1st calibration = 24 hours after sensor insertion.
    • 2nd calibration = 2 to 12 hours after 1st successful calibration.
    • 3rd calibration = 2 to 12 hours after 2nd successful calibration.
    • 4th calibration = 2 to 12 hours after 3rd successful calibration.
  • Glucose readings will start displaying in the app a few minutes after the 2nd calibration is successfully completed.

The sensor requires a 24-hour Warm-Up Phase to stabilize in your body before glucose values will be collected by the smart transmitter. During the Warm-Up Phase, you do not need to wear the smart transmitter. If you decide to wear the smart transmitter over the sensor during this time, you will receive a message on the app indicating the Warm-Up Phase is in progress. Once the Warm-Up Phase is complete, turn ON the smart transmitter and place it over the sensor with the Eversense® adhesive patch. The system will prompt you to calibrate using the app.

Still have questions?

The Eversense team is dedicated and ready to provide the answers and support you need. Simply click the link below.

The Eversense® 365 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to one year in people (18 years and older) with diabetes. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are required for calibration one time a week after day 13, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense 365 CGM System is a prescription device; patients should talk to their health care provider to learn more.

For important safety information, see bit.ly/eversensesafety

Eversense, Eversense 365 Continuous Glucose Monitoring, and the Eversense logo are trademarks of Senseonics, Incorporated. All other trademarks are properties of their respective owners and are used solely for informative purposes. No relationship or endorsement should be inferred or implied.


Apple Watch® is a product of Apple, Inc., and may be separately purchased from an authorized Apple retailer. Apple Watch is not included with the Eversense CGM System. Android is a trademark of Google LLC.

 

MKT-001692 Rev 1